Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodevelopmental Disorders and Oncology Target Validation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IQSEC2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IQSEC2 Recombinant Protein (SEC7 Domain / Full Length) High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. |
View IQSEC2 Products |
| Gene Delivery | IQSEC2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and neuron transduction. |
View IQSEC2 Products |
| Benchmark Ab | Anti-IQSEC2 Antibody Recombinant positive control for western blot and immunoprecipitation. |
View IQSEC2 Products |
| Validator | IQSEC2 siRNA Set For target knockdown and specificity verification. |
View IQSEC2 Products |
| Related Target A | ARF6 Downstream small GTPase directly activated by IQSEC2 GEF activity. |
View ARF6 Products |
| Related Target B | DLG4 Synaptic scaffolding protein (PSD-95) that anchors IQSEC2. |
View DLG4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular target accessibility & modeling | Lentiviral vectors optimized for high-efficiency expression in primary neurons |
| SEC7 domain homology screening | Sequence-verified recombinant SEC7 domains with >95% purity by SDS-PAGE |
| Lack of clinical/assay controls | Recombinant benchmark antibodies available for validation assays |
| False positives in knockdown studies | Sequence-verified siRNA pool included for precise target gene knockdown |
Live IQSEC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IQSEC2 therapeutics is intensifying, with major players shifting focus from traditional symptomatic treatments to precision genetic medicines and targeted small molecules. As first-generation therapies reach the clinic, the next wave of R&D is targeting the modulation of the IQSEC2-ARF6 signaling axis in both neurodevelopmental disorders and invasive cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antisense Oligonucleotides (ASO) | Academic Medical Centers, Biotech Startups | IQSEC2-Associated Encephalopathy, Epilepsy | Target Knockdown Validation (Need sequence-verified siRNA & Lentivirus) |
| Small Molecule Inhibitors | Oncology-focused Biopharma | Invasive Breast Cancer, Prostate Cancer | GEF Activity Assay (Need highly purified recombinant SEC7 domains) |
| Gene Therapy (AAV/Lentivirus) | Neuro-genetic Therapeutics Developers | X-linked Intellectual Disability (XLID) | Overexpression & Localization (Need high-titer Lentivirus ORF) |